NPMC
Click Here to Subscribe!

E-Health Services

Daily Health News

  Latest News
  FDA Approvals
  FYI

Health Information

Newsletter Topics

Alzheimer's Disease
Anxiety
Arthritis
Blood Pressure
Breast Cancer
Cancer
Depression
Diabetes
Exercise / Fitness
Female Urological Disorders
Gastrointestinal Health
Healthy Diet
Heart Disease
Men's Health
Menopause
Neurology
Orthopedics
Pain Management
Parenting
Pediatrics
Pregnancy
Senior Caregiving
Seniors' Health
Sleep Disorders
Sports Medicine
Stroke
Weight Management
Women's Health
Women's Heart Health
Username: Password: Forgot password?
Remember me next time.
 FDA Approvals
Return to
Daily Health Main Page.

  Bavencio Approved for Rare Skin Cancer
 
  First sanctioned treatment in U.S. for aggressive tumor

 

THURSDAY, March 23, 2017 (HealthDay News) -- Bavencio (avelumab) has been approved by the U.S. Food and Drug Administration to treat a rare but aggressive form of skin cancer called Merkel cell carcinoma (MCC), the agency said Thursday in a news release.

The drug, sanctioned for people 12 and older, is the first MCC treatment approved in the United States. Some 1,600 people in the U.S. are diagnosed annually with the disease. Many cases can be treated surgically, but about half of those diagnosed will have their cancers recur, and the cancer will spread (metastasize) in some 30 percent of cases, the FDA said.

Bavencio targets a protein found on some cancer cells, helping the body's immune system attack these cells, the FDA said.

The drug was evaluated in a clinical study of 88 people with spreading MCC. About one-third of trial participants given Bavencio had a complete or partial shrinkage of tumors, the agency said.

Bavencio's common side effects included fatigue, bone and muscle pain, diarrhea, nausea, skin reaction, lack of appetite and swelling of the limbs. More serious side effects occurred when the immune system attacked healthy cells or organs, including the lungs, liver, colon and kidneys, the FDA said.

Approval of Bavencio was granted to EMD Serono, a Germany-based unit of Merck & Co., and Pfizer.

More information

The FDA has more about this approval.

  Print
 
 More  FDA Approvals
 
   •  New Parkinson's Drug Xadago Approved
  To help prevent 'off' episodes among users of levodopa/carbidopa
 
   •  Noctiva Approved for Frequent Urination at Night
  For adults who awaken to urinate at least twice nightly
 
   •  Xermelo Approved for Tumor-Related Diarrhea
  Drug will treat a condition called carcinoid syndrome diarrhea
 
   •  Siliq Approved for Plaque Psoriasis
  Injected drug is for use by patients who've failed other treatments
 
Health Content Provided By:
The health content is provided for informational and educational purposes. It is intended for the general population and may not reflect specific conditions or risk of an individual or segment of the population. Therefore, it is not intended to be a substitute for professional medical advice, consultation, treatment or diagnosis. Always seek the advice of your physician or other qualified health provider with questions. Never disregard professional medical advice or delay in seeking it because of information obtained through these services.
E-Home | E-Health Services | Sample News | Subscribe | Feedback | Contact Us | Privacy Policy | Terms & Conditions
 
© 2010 NATIONAL MEDICAL CENTER · 1910 MALVERN AVE · HOT SPRINGS, ARKANSAS 71901 · 501-321-1000 · SITEMAP · PRIVACY POLICY · TERMS & CONDITIONS -
 
ABOUT US SERVICES & TECHNOLOGY FOR PATIENTS & GUESTS FOR PHYSICIANS FOR EMPLOYEES COMMUNITY CAREERS